Revenue rose 9.2% to ₹1,901 crore, compared with ₹1,732 crore in the same period last year, driven by growth in contract research (CRDMO), sterile injectables and generics.
Earnings before interest, taxes, depreciation and amortisation (EBITDA) grew 14% to ₹302 crore, while EBITDA margin improved to 15.3% from 14.5% a year ago.
Radiopharma revenue rose 3% year-on-year to ₹271 crore, supported by continued growth in PET imaging product Ruby-Fill.
Revenue from the radiopharmacy segment grew 5% to ₹598 crore, although margins remained under pressure due to increased competition in the SPECT imaging business.
CDMO Sterile Injectables revenue increased 14% to ₹370 crore, driven by higher sales volumes and strong customer interest in Line 3 at the Spokane facility.
In the CRDMO segment, drug discovery revenue surged 42% to ₹161 crore, while the API business posted a 9% rise in revenue to ₹141 crore.
The generics business registered a 7% increase in revenue to ₹166 crore, with improved margins attributed to a strategic focus on profitable product lines.
Clinical trials for proprietary drug candidates JBI-802 and JBI-778 are progressing as planned, the company said.
The company said it remains committed to its Vision 2030 strategy, with ongoing investments in radiopharma, CRDMO and sterile injectables to drive long-term growth. Net debt to EBITDA rose slightly to 1.2x from 1.1x in March due to higher capital expenditure.
Jubilant Pharmova shares were trading 2% lower after the announcement of its results, at a price of ₹1,150.20 on the BSE. The stock has shown a strong yearly performance with a 52.61% rise year-to-date.
First Published: Jul 29, 2025 2:18 PM IST
